Indonesia pursues blood plasma domestic production

The government continues to encourage the resilience of the domestic pharmaceutical sector through plasma fractionation, namely the use of blood plasma to produce medicinal products. So far, the need for plasma fractionation is still completely dependent on imports. To overcome this, the Indonesia Investment Authority (INA) signed a Term Sheet between Indonesia, as a state-owned body that manages investment funds with SK Plasma.